aDepartment of Clinical Pharmacology, Flinders University School of Medicine, Flinders Medical Center, Bedford Park, Australia
bDepartment of Toxicology, Institute of Pharmacology and Toxicology, University of Tuebingen, Tuebingen, Germany
cDivision of Pathology and Neuroscience, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
dPharmacogenomics Laboratory, Molecular Endocrinology and Oncology Research Centre, CHUL Research Centre, Faculty of Pharmacy, Laval University, Quebec, Canada
eBiotechnology Research Centre, Faculty of Engineering, Toyama Prefectural University, Kosugi, Toyama, Japan
fBiometal Science Laboratory, RIKEN Harima Institute, Mikazuki-cho, Sayo-gun, Hyogo, Japan
gHeritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
hDepartment of Environmental Health and Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati Ohio, USA
Sponsorship: This work has been supported, in part, by the Australian National Health and Medical Research Council (P.I.M., J.O.M.), NIH Grant P30 ES06096 (D.W.N.), Canadian Institutes of Health Research (CIHR; 117282) and Canada Research Chair Program (C.G.). P.I.M. is a NHMRC Senior Principal Research Fellow.
Correspondence and requests for reprints to Professor Peter Mackenzie, Department of Clinical Pharmacology, Flinders University School of Medicine, Flinders Medical Centre, Bedford Park, SA 5050, Australia.
E-mail: peter.mackenzie@flinders.edu.au
Received 23 May 2005 Accepted 4 June 2005
